Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983328 | 0.83 | CASP3 (0.46) | TLR2CASP3PTPN1 | |
| SCHEMBL30983329 | 0.83 | CASP3 (0.46) | TLR2CASP3PTPN1 | |
| SCHEMBL31550488 | 0.81 | SIRT2 (0.49) | TLR2SIRT2 | |
| SCHEMBL31191799 | 0.81 | CASP3 (0.53) | TLR2CASP3MDM2 | |
| SCHEMBL31550491 | 0.75 | KMT2A (0.47) | CASP3 | |
| SCHEMBL31550490 | 0.75 | SIRT2 (0.53) | SIRT2 | |
| SCHEMBL26923683 | 0.74 | CASP3 (0.54) | TLR2CASP3PTPN1 | |
| SCHEMBL20964457 | 0.73 | TLR2 (0.54) | TLR2CASP3MDM2 | |
| SCHEMBL16450234 | 0.72 | CASP3 (0.59) | TLR2CASP3MDM2 | |
| SCHEMBL31217980 | 0.72 | CASP3 (0.54) | CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332272-A1 | PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF | MEDILINK THERAPEUTICS SUZHOU CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| EP-4534104-A1 | PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332272-A1 | PREPARATION METHOD FOR DRUG LINKER CONJUGATE AND INTERMEDIATE THEREOF | SI, PAICS, FURIN | TLR2 2026/4885CASP3 4253/4885SIRT2 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.